With a proven track record of scaling category-defining companies, we’re partnering with the next generation of innovators, pushing the boundaries of science and bringing life-changing treatments from bench to bedside.
Our investment focus encompasses therapeutics (small molecules, biologics, gene and cell therapies, precision medicine), diagnostics and devices (early-revenue and innovative platforms), and digital health and healthcare services (early revenue-stage cutting-edge models for improving care).
We back pioneering innovations that have the potential to fundamentally change patient care.
More than just capital, we provide deep industry expertise, operational guidance, and a global network to accelerate company growth.
We invest in companies at critical inflection points, from early-stage breakthroughs to scalable healthcare solutions, ensuring they reach their full potential.
We’re looking for companies at critical inflection points that need both capital and strategic partners to work alongside founders to translate breakthrough science into transformative solutions. We are therapeutic modality agnostic and are looking for innovation, strong science and clinical rationale, scalability and market potential, experienced and mission-driven teams, and a strategic fit. We’re interested in:
Transformative treatments and scalable platforms with differentiated lead programs in or approaching clinical trials. We look for clear potential for pipeline expansion and long-term impact, whether small molecules, biologics, gene or cell therapies, or other cutting-edge approaches.
Technologies that enable earlier, more accurate disease detection and treatment personalization, with a focus on early revenue-stage companies poised for sustainable growth and market expansion.
Data-driven solutions that improve patient outcomes, streamline care delivery, and/or create more efficient healthcare models. We prioritize early revenue-stage companies, supporting their growth into enduring and impactful businesses.
If you’re building something extraordinary,
We aim to respond to promising
opportunities within a few weeks.
As we believe collaboration drives innovation, we actively partner with like-minded investors to support the most promising healthcare and life science companies. Whether leading, co-leading, or joining a syndicate, we bring deep industry expertise, strategic insights, and a commitment to building sustainable, high-impact businesses.
We partner with top-tier venture funds, family offices, and strategic investors to build strong syndicates that provide both capital and expertise.
Our team brings decades of experience in biotech, healthcare, and venture investing, offering scientific and commercial diligence, operational insights, and strategic support.
We are hands-on investors, working closely with portfolio companies post-investment to maximize value creation and ensure long-term success.
We invest across different stages, from early-stage companies to ones in growth-stage that are scaling revenue.